The Protective Efficacy of Chlamydial Protease-like Activity Factor Vaccination is Dependent Upon CD4+ T Cells

Overview

Journal Cell Immunol

Publisher Elsevier

Specialties Allergy & Immunology
Cell Biology

Date 2006 Nov 23

PMID 17116296

Citations 29

Authors

Cathi Murphey

Ashlesh K Murthy

Patricia A Meier

M Neal Guentzel

Guangming Zhong

Bernard P Arulanandam

Affiliations

Soon will be listed here.

Abstract

We have previously determined the protective efficacy of intranasal vaccination with chlamydial protease-like activity factor (CPAF) against genital chlamydial infection. Since T-helper 1 (Th1) responses are important for anti-chlamydial immunity, we examined the contribution of CD4(+) T cells in CPAF mediated immunity against intravaginal (i.vag.) Chlamydia muridarum infection in C57BL/6 mice. CPAF+IL-12 vaccination induced antigen-specific CD4(+) T cells that secreted elevated levels of IFN-gamma, and generated strong humoral responses. The protective effects of CPAF vaccination against genital chlamydial challenge were abrogated by anti-CD4 neutralizing antibody treatment. Moreover, anti-chlamydial immunity could be adoptively transferred to naïve recipients using CPAF-specific CD4(+) T cells. Therefore, CPAF mediated anti-chlamydial immunity is highly dependent upon antigen-specific CD4(+) T cells.

Citing Articles

Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.

Poston T, Girardi J, Kim M, Zwarycz P, Polson A, Yount K Vaccine. 2024; 43(Pt 1):126526.

PMID: 39536454 PMC: 11817958. DOI: 10.1016/j.vaccine.2024.126526.

Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.

Yount K, Darville T Vaccines (Basel). 2024; 12(8).

PMID: 39203989 PMC: 11359697. DOI: 10.3390/vaccines12080863.

Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.

Poston T, Girardi J, Polson A, Bhardwaj A, Yount K, Jaras Salas I Mucosal Immunol. 2024; 17(5):1005-1018.

PMID: 38969067 PMC: 11495396. DOI: 10.1016/j.mucimm.2024.06.012.

Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Vaccine.

Richardson S, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme J Front Immunol. 2021; 12:698737.

PMID: 34249004 PMC: 8264281. DOI: 10.3389/fimmu.2021.698737.

Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses.

Pais R, Omosun Y, Igietseme J, Fujihashi K, Eko F Front Immunol. 2019; 10:1577.

PMID: 31333682 PMC: 6621642. DOI: 10.3389/fimmu.2019.01577.

References

Wang S, Fan Y, Brunham R, Yang X . IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol. 1999; 29(11):3782-92. DOI: 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B. View

Zhong G, Liu L, Fan T, Fan P, Ji H . Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med. 2000; 191(9):1525-34. PMC: 2213440. DOI: 10.1084/jem.191.9.1525. View

Morrison S, Su H, Caldwell H, Morrison R . Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun. 2000; 68(12):6979-87. PMC: 97807. DOI: 10.1128/IAI.68.12.6979-6987.2000. View

Morrison S, Morrison R . Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun. 2001; 69(4):2643-9. PMC: 98202. DOI: 10.1128/IAI.69.4.2643-2649.2001. View

Arulanandam B, Lynch J, Briles D, Hollingshead S, Metzger D . Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun. 2001; 69(11):6718-24. PMC: 100048. DOI: 10.1128/IAI.69.11.6718-6724.2001. View

Moore T, Ananaba G, Bolier J, Bowers S, Belay T, Eko F . Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002; 105(2):213-21. PMC: 1782645. DOI: 10.1046/j.0019-2805.2001.01354.x. View

Morrison R, Caldwell H . Immunity to murine chlamydial genital infection. Infect Immun. 2002; 70(6):2741-51. PMC: 128027. DOI: 10.1128/IAI.70.6.2741-2751.2002. View

Kelly K . Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms. Int Rev Immunol. 2003; 22(1):3-41. DOI: 10.1080/08830180305229. View

Huber V, Arulanandam B, Arnaboldi P, Elmore M, Sheehan C, Kallakury B . Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol. 2003; 3(6):801-9. DOI: 10.1016/S1567-5769(02)00233-3. View

10.

Moore T, Ekworomadu C, Eko F, Macmillan L, Ramey K, Ananaba G . Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis. 2003; 188(4):617-24. DOI: 10.1086/377134. View

11.

Zhong G, Reid R, Brunham R . Mapping antigenic sites on the major outer membrane protein of Chlamydia trachomatis with synthetic peptides. Infect Immun. 1990; 58(5):1450-5. PMC: 258646. DOI: 10.1128/iai.58.5.1450-1455.1990. View

12.

Ramsey K, Rank R . Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect Immun. 1991; 59(3):925-31. PMC: 258348. DOI: 10.1128/iai.59.3.925-931.1991. View

13.

Rank R . Animal models for urogenital infections. Methods Enzymol. 1994; 235:83-93. DOI: 10.1016/0076-6879(94)35133-3. View

14.

Igietseme J, Ramsey K, Magee D, Williams D, Kincy T, Rank R . Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg Immunol. 1993; 5(6):317-24. View

15.

Igietseme J, Magee D, Williams D, Rank R . Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones. Infect Immun. 1994; 62(11):5195-7. PMC: 303248. DOI: 10.1128/iai.62.11.5195-5197.1994. View

16.

Whittum-Hudson J, An L, Saltzman W, PRENDERGAST R, MacDONALD A . Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat Med. 1996; 2(10):1116-21. DOI: 10.1038/nm1096-1116. View

17.

Williams D, Grubbs B, Pack E, Kelly K, Rank R . Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Infect Immun. 1997; 65(7):2876-82. PMC: 175404. DOI: 10.1128/iai.65.7.2876-2882.1997. View

18.

Arulanandam B, Metzger D . Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999; 17(3):252-60. DOI: 10.1016/s0264-410x(98)00157-1. View

19.

Arulanandam B, OToole M, Metzger D . Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999; 180(4):940-9. DOI: 10.1086/314996. View

20.

Murthy A, Sharma J, Coalson J, Zhong G, Arulanandam B . Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell Immunol. 2004; 230(1):56-64. DOI: 10.1016/j.cellimm.2004.09.002. View